{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T15:07:02Z","timestamp":1773673622715,"version":"3.50.1"},"reference-count":24,"publisher":"PAGEPress Publications","issue":"1","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatol Reports"],"abstract":"<jats:p>The Psoriasis Area and Severity Index (PASI) is widely used to evaluate psoriatic disease activity in clinical settings; however, its limitations hinder its practicality in routine use. The Simple-Measure for Assessing Psoriasis Severity (S-MAPA) has emerged as a promising tool addressing these limitations, providing a more feasible approach for assessing disease severity. This study aimed to evaluate the S-MAPA as a sensitive and practical alternative to existing instruments for measuring psoriasis severity. Patients with psoriasis were assessed using body surface area (BSA), the Physician\u2019s Global Assessment (PGA), S-MAPA, PASI, and Dermatology Life Quality Index (DLQI). Plasma high-sensitivity C-reactive protein (hs-CRP) levels were also measured. Spearman\u2019s correlation analysis compared the relationships between these assessment tools and hs-CRP levels. In total, 100 assessments were conducted between January and July 2019. The S-MAPA score and PASI showed a strong positive correlation with disease severity (r=0.9315, p&lt;0.01). Both the S-MAPA score exhibited comparable correlations with hs-CRP levels (r=0.5299 vs. 0.5316) and the DLQI (r=0.2533 vs. 0.2641). The S-MAPA score demonstrated stronger correlations with the PASI, DLQI, and hs-CRP level than with BSA or the PGA score. The area under the receiver operating characteristic curve for the S-MAPA was 0.9787, with an optimal cut-off value of 138 for predicting severe psoriasis (sensitivity, 92.59%; specificity, 95.89%). Based on our findings, the S-MAPA is a reliable and practical alternative for assessing the severity of psoriasis in clinical practice, offering advantages over conventional measures.<\/jats:p>","DOI":"10.4081\/dr.2025.10231","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T03:38:44Z","timestamp":1748403524000},"source":"Crossref","is-referenced-by-count":0,"title":["S-MAPA: bridging the gap in psoriasis severity assessment"],"prefix":"10.4081","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1408-5343","authenticated-orcid":false,"given":"Trang Thi Thuy","family":"Vu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8978-6182","authenticated-orcid":false,"given":"Chuyen Thi Hong","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9453-7172","authenticated-orcid":false,"given":"Trung","family":"The Van","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2549","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"key":"36691","doi-asserted-by":"crossref","unstructured":"1. Puzenat E, Bronsard V, Prey S, et al. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. J Eur Acad Dermatol Venereol 2010;24:10-6.","DOI":"10.1111\/j.1468-3083.2009.03562.x"},{"key":"36692","doi-asserted-by":"crossref","unstructured":"2. Spuls PI, Lecluse LL, Poulsen M-LN, et al. How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. J Invest Dermatol 2010;130:933-43.","DOI":"10.1038\/jid.2009.391"},{"key":"36693","doi-asserted-by":"crossref","unstructured":"3. Van de Kerkhof P. On the limitations of the psoriasis area and severity index (PASI). Br J Dermatol 1992;126:205-6.","DOI":"10.1111\/j.1365-2133.1992.tb07827.x"},{"key":"36694","doi-asserted-by":"crossref","unstructured":"4. Walsh JA, Arledge T, Nurminen T, et al. PGA\u00d7 BSA: a measure of psoriasis severity tested in patients with active psoriatic arthritis and treated with certolizumab pegol. J Rheumatol 2018;45:922-8.","DOI":"10.3899\/jrheum.170244"},{"key":"36695","doi-asserted-by":"crossref","unstructured":"5. Walsh JA, McFadden M, Woodcock J, et al. Product of the Physician Global Assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort. J Am Acad Dermatol 2013;69:931-7.","DOI":"10.1016\/j.jaad.2013.07.040"},{"key":"36696","doi-asserted-by":"crossref","unstructured":"6. Chiesa Fuxench ZC, Callis Duffin K, Siegel M, et al. Validity of the Simple-Measure for Assessing Psoriasis Activity (SMAPA) for objectively evaluating disease severity in patients with plaque psoriasis. J Am Acad Dermatol 2015;73:868-70.","DOI":"10.1016\/j.jaad.2015.07.001"},{"key":"36697","doi-asserted-by":"crossref","unstructured":"7. Boehncke WH. Systemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and Consequences. Front Immunol 2018;9:579.","DOI":"10.3389\/fimmu.2018.00579"},{"key":"36698","doi-asserted-by":"crossref","unstructured":"8. Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005;64 Suppl 2:ii65-8; discussionii9-73.","DOI":"10.1136\/ard.2004.031237"},{"key":"36699","doi-asserted-by":"crossref","unstructured":"9. Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician\u2019s Global Assessment. J Am Acad Dermatol 2004;51:563-9.","DOI":"10.1016\/j.jaad.2004.04.012"},{"key":"36700","doi-asserted-by":"crossref","unstructured":"10. Carlin CS, Feldman SR, Krueger JG, et al. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol 2004;50:859-66.","DOI":"10.1016\/j.jaad.2003.09.014"},{"key":"36701","doi-asserted-by":"crossref","unstructured":"11. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) \u2013 a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-6.","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"36702","doi-asserted-by":"crossref","unstructured":"12. Hongbo Y, Thomas CL, Harrison MA, et al. Translating the science of quality of life into practice: What do dermatology life quality index scores mean? J Invest Dermatol 2005;125:659-64.","DOI":"10.1111\/j.0022-202X.2005.23621.x"},{"key":"36703","doi-asserted-by":"crossref","unstructured":"13. \u015eener G, \u0130nan Yuksel E, G\u00f6kdeniz O, et al. The Relationship of Hematological Parameters and C-reactive Protein (CRP) With Disease Presence, Severity, and Response to Systemic Therapy in Patients With Psoriasis. Cureus 2023;15:e43790.","DOI":"10.7759\/cureus.43790"},{"key":"36704","unstructured":"14. Mukaka MM. Statistics corner: A guide to appropriate use of correlation coefficient in medical research. Malawi Med J 2012;24:69-71."},{"key":"36705","doi-asserted-by":"crossref","unstructured":"15. Naldi L, Svensson A, Diepgen T, et al. Randomized clinical trials for psoriasis 1977-2000: the EDEN survey. J Invest Dermatol 2003;120:738-41.","DOI":"10.1046\/j.1523-1747.2003.12145.x"},{"key":"36706","unstructured":"16. Duffin KC, Papp KA, Bagel J, et al. Evaluation of the Physician Global Assessment and Body Surface Area Composite Tool for Assessing Psoriasis Response to Apremilast Therapy: Results from ESTEEM 1 and ESTEEM 2. J Drugs Dermatol 2017;16:147-53."},{"key":"36707","doi-asserted-by":"crossref","unstructured":"17. Merola JF, Gottlieb AB. Practical assessment of psoriasis clinical severity in both clinical trials and clinical practice settings: a report from the GRAPPA 2016 annual meeting. J Rheumatol 2017;44:691-2.","DOI":"10.3899\/jrheum.170147"},{"key":"36708","doi-asserted-by":"crossref","unstructured":"18. Kural BV, \u00d6rem A, \u00c7im\u015fit G, et al. Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant-antioxidant system in patients with psoriasis. Clin Chim Acta 2003;328:71-82.","DOI":"10.1016\/S0009-8981(02)00373-X"},{"key":"36709","doi-asserted-by":"crossref","unstructured":"19. Mallbris L, Granath F, Hamsten A, St\u00e5hle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 2006;54:614-21.","DOI":"10.1016\/j.jaad.2005.11.1079"},{"key":"36710","doi-asserted-by":"crossref","unstructured":"20. Vadakayil AR, Dandekeri S, Kambil SM, Ali NM. Role of C-reactive protein as a marker of disease severity and cardiovascular risk in patients with psoriasis. Indian Dermatol Online J 2015;6:322.","DOI":"10.4103\/2229-5178.164483"},{"key":"36711","doi-asserted-by":"crossref","unstructured":"21. Kimball AB, Wu Y. Cardiovascular disease and classic cardiovascular risk factors in patients with psoriasis. Int J Dermatol 2009;48:1147-56.","DOI":"10.1111\/j.1365-4632.2009.04075.x"},{"key":"36712","doi-asserted-by":"crossref","unstructured":"22. Barrea L, Macchia PE, Tarantino G, et al. Nutrition: A key environmental dietary factor in clinical severity and cardiometabolic risk in psoriatic male patients evaluated by 7-day food-frequency questionnaire. J Transl Med 2015;13:1-10.","DOI":"10.1186\/s12967-015-0658-y"},{"key":"36713","unstructured":"23. Uaratanawong R, Uaratanawong S, Chunhasewee C, Chawvavanich P. High Sensitivity C-Reactive Protein Level and Psoriasis Severity in Thai Patients. J Med Assoc Thai 2016;99:1039-45."},{"key":"36714","doi-asserted-by":"crossref","unstructured":"24. Coimbra S, Oliveira H, Reis F, et al. C-reactive protein and leucocyte activation in psoriasis vulgaris according to severity and therapy. J Eur Acad Dermatol Venereol 2010;24:789-96.","DOI":"10.1111\/j.1468-3083.2009.03527.x"}],"container-title":["Dermatology Reports"],"original-title":[],"link":[{"URL":"https:\/\/journals.pagepress.net\/dr\/article\/download\/10231\/9670","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.pagepress.net\/dr\/article\/download\/10231\/9889","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.pagepress.net\/dr\/article\/download\/10231\/9670","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T13:47:41Z","timestamp":1773668861000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.pagepress.net\/dr\/article\/view\/10231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2,12]]}},"URL":"https:\/\/doi.org\/10.4081\/dr.2025.10231","relation":{},"ISSN":["2036-7406","2036-7392"],"issn-type":[{"value":"2036-7406","type":"electronic"},{"value":"2036-7392","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,28]]}}}